Alibaba Group has priced an HK$80 billion share placement to fund artificial intelligence investment and expand its AI infrastructure. The Chinese technology group will issue 710 million new ordinary shares at HK$112.70 each. The deal is worth about US$10.2 billion at current exchange rates. Alibaba expects the transaction to close on Aug. 26, subject to customary conditions. The fundraising follows a sharp increase in Alibaba’s spending on computing infrastructure, with capital expenditure reaching RMB67.68 billion during the quarter ended June 30.

The 2,758-TEU PanStar Acro left Busan New Port at about 9 p.m. on August 22. The ship will use the Northern Sea Route before calling at three European ports. The vessel is carrying 837 TEU during the Arctic shipping trial, including chemical products, used vehicles, and automotive parts. The trial will gather operating data throughout the voyage, marking South Korea’s first trial of the Northern Sea Route with a container ship.

The written statement submitted by the Ministry for Narcotics Control detailed that Saudi Arabia accounted for the vast majority of repatriations, expelling 15,500 Pakistani nationals during the four-month window. The United Arab Emirates deported 3,803 individuals, followed by Oman with 1,606 deportations, Bahrain with 521, Qatar with 429, and Kuwait with 97. A significant subset of the repatriated individuals involved 4,628 absconders, 1,294 individuals who served prison sentences, and 472 individuals specifically identified as beggars.

Australian researchers from Adelaide University and the Olivia Newton-John Cancer Research Institute have identified a novel molecular switch that drives the spread of aggressive tumors. Published in EMBO Molecular Medicine, the breakthrough study reveals that Australian researchers uncover a promising new way to tackle triple-negative breast cancer by restoring a critical regulatory molecule known as miR-342. The discovery opens new avenues to prevent life-threatening secondary cancers in organs such as the lungs and bones. Triple-negative breast cancer accounts for 10% to 15% of Australia’s approximately 21,000 annual breast cancer diagnoses but causes a disproportionate number of deaths. Lead investigators demonstrated that when miR-342 levels fall, a cancer-driving pathway called E2F becomes overactive, allowing dormant cancer cells to spread throughout the body and form dangerous secondary tumors. In pre-clinical models, scientists demonstrated that restoring miR-342 levels markedly reduced the spread of cancer cells to distant organs. Furthermore, researchers discovered that palbociclib, an existing CDK4/6 inhibitor drug currently approved for hormone receptor-positive breast cancers, significantly halted metastatic tumor growth in models exhibiting low miR-342 levels. The findings suggest measuring miR-342 levels could allow doctors to repurpose existing therapeutics to treat high-risk patients. Co-senior author Associate Professor Philip Gregory from Adelaide University’s Centre for Cancer Biology confirmed that preventing metastasis remains the primary challenge in treating aggressive breast cancers. Gregory emphasized that because palbociclib targets the overactive E